(P040) Radiosurgery for Primary Central Nervous System Lymphoma

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

SRS appears to be a reasonable treatment option for focally persistent or recurrent PCNSL in select patients, especially in the setting of focal neurologic deficits. As a radiosensitive entity, all PCNSL lesions had a substantial volumetric reduction with at least 14 Gy, and all patients with a focal neurologic deficit at treatment experienced symptomatic improvement with SRS. Further investigation should be completed regarding the benefits of SRS for focally appearing PCNSL as a potential way to avoid neurotoxicity and improve symptoms in selected patients.

Zachary A. Seymour, MD, Sarah Westcott, James L. Rubenstein, Penny K. Sneed, MD; Department of Radiation Oncology, Department of Medicine, University of California, San Francisco

BACKGROUND AND PURPOSE: The role of stereotactic radiosurgery (SRS) in primary central nervous system lymphoma (PCNSL) is unknown. This represents a case series of five patients treated with SRS for PCNSL.

METHODS: All patients who were treated with SRS for PCSNL were retrospectively reviewed. All clinical and treatment parameters were evaluated to assess treatment outcomes, symptomatic response, complications, and disease control. Near-complete response was defined as ≥ 75% volumetric reduction from the time of treatment.

RESULTS: A total of five patients with PCNSL underwent SRS to seven lesions following 5–10 cycles of chemotherapy, which consisted of a regimen of high-dose methotrexate, rituximab, and temozolomide, with the last administration at least 14 days before SRS. Three patients were treated with SRS in lieu of whole-brain radiotherapy (WBRT), one patient was treated for salvage SRS after focal failure after WBRT, and one patient received no adjuvant radiation following chemotherapy and was treated only at the time of focal recurrence. The median age at the time of SRS was 60 years (range: 44–75 yr). The median imaging follow-up post-SRS was 16.8 months (range: 1.2–46.9 mo). The median dose was 15 Gy (range: 14–17 Gy), with a median prescription isodose line of 50% for a median target volume of 2.76 mL (range: 0.69–14.6 mL). All lesions had at least a near-complete response, with 82% response being the smallest volumetric reduction and four lesions obtaining a complete response. No patients experienced a local failure. Prior to SRS treatment, four patients had focal neurologic deficits, all of which improved with SRS. No neurotoxicity or adverse effects were observed. Whole-brain control was not achieved in any patient, with a median time to distant brain failure of 2.3 months (range: 0.7–21.6 mo) after first SRS treatment, and two patients had salvage SRS for a focal distant recurrence 3 and 33 months after initial SRS, respectively.

CONCLUSIONS: SRS appears to be a reasonable treatment option for focally persistent or recurrent PCNSL in select patients, especially in the setting of focal neurologic deficits. As a radiosensitive entity, all PCNSL lesions had a substantial volumetric reduction with at least 14 Gy, and all patients with a focal neurologic deficit at treatment experienced symptomatic improvement with SRS. Further investigation should be completed regarding the benefits of SRS for focally appearing PCNSL as a potential way to avoid neurotoxicity and improve symptoms in selected patients.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Related Content